NCT00916357View on ClinicalTrials.gov

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Humalog

DRUG

Humulin-R

DRUG

Recombinant human hyaluronidase PH20 (rHuPH20)

Trial Locations (1)

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT00916357 - Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter